Compare 10X Genomics Inc (TXG) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs ProShares Ultra Semiconductors — how do they compare? 10X Genomics Inc trades at $78.6 (market cap $9.92B), while ProShares Ultra Semiconductors trades at $98.89 (market cap $3.15B). The key difference: 10X Genomics Inc is far larger — about 3.1× ProShares Ultra Semiconductors's market cap, and ProShares Ultra Semiconductors is more actively traded (333,862 versus 9,372,166). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 92 Days and ProShares Ultra Semiconductors for 29 Days on average.
| TXG | USD | |
|---|---|---|
Market Cap | $9.92B | $3.15B |
Volume | 9,372,166 | 333,862 |
Sector | Health | Leveraged / Inverse |
52-Week High | $97.74 | $113.53 |
52-Week Low | $11.48 | $43.19 |
Typical Hold Time | 92 Days | 29 Days |
Enterprise Value | $9.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
USD stock trades at $102.77, down 0.96% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong momentum indicators with ADX signaling trend strength, though RSI levels suggest potential overbought conditions. Recent corporate action includes a $0.13 dividend scheduled for September 2026. Support levels are established at $100-$102, with resistance at $103-$105.
The stock's technical strength contrasts with limited fundamental data availability. Investment opportunity lies in the bullish technical setup and dividend yield, while risks include potential overbought conditions and lack of current financial metrics. Investors should await updated financial reports for fundamental validation of the current price level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
